AKT1 and gastric cancer: Our results confirmed that EBV-positive gastric cancer cells are resistant to 5-FU and that this resistance is reduced when the expression of phosphorylated nuclear factor kappaB (p-NFκB) and phosphorylated AKT (p-AKT) is decreased by combining 5-FU with LY294002, a PI3K inhibitor (Figure 3).